The defining features of Alzheimer's disease (AD) include neurodegeneration, a decline in cognition, and tau and amyloid-β protein pathologies. Sleep problems affect many individuals with AD and could be an aggravating factor in the disease because it creates a barrier to the glymphatic system's ability to clear neurotoxic proteins, disrupt the plasticity of synapses, and increase neuroinflammation. Suvorexant, which works as a dual orexin receptor antagonist, has proven effective in the management of sleep problems by fine-tuning the orexin system, which regulates arousal. Preliminary studies indicate that, in addition to improving sleep, Suvorexant could potentially help in the reduction of amyloid and tau buildup, as well as the improvement of synaptic activity and reduction of neuroinflammation. Recent clinical studies show improvements in sleep quality among older adults, in addition to safety and efficacy, and suggest increasing cognitive functioning in mild cognitive impairment and early AD. This review summarizes the existing research on the potential of Suvorexant as a therapeutic to address the mechanisms of orexin signaling in AD, as well as the sleep-targeted interventions to address the symptoms and modify the disease to improve cognitive functioning. We also emphasize future research directions such as cognitive outcomes over extended periods, potential optimal dosing, and combinatory strategies with lifestyle and/or medication therapies. This review will discuss the current evidence regarding the therapeutic effects of suvorexant and orexin signaling in AD.
JavaidSFGiebelCKhanMA, et al.Epidemiology of Alzheimer’s disease and other dementias: rising global burden and forecasted trends. F1000Res2021; 10: 425.
2.
ZhangNChaiSWangJ. Assessing and projecting the global impacts of Alzheimer’s disease. Front Public Health2025; 12: 1453489.
HarshSRatherHJDwivediA, et al.The neuropsychology of chronic neurological disorders: a review of cognitive and emotional impairments. Cureus2025; 17: e93642.
5.
JellingerKA. Neuropathological assessment of the Alzheimer spectrum. J Neural Transm2020; 127: 1229–1256.
6.
GarbuzDZatsepinaOEvgen’evM. Beta amyloid, tau protein, and neuroinflammation: an attempt to integrate different hypotheses of Alzheimer’s disease pathogenesis. Mol Biol2021; 55: 670–682.
7.
RaufABadoniHAbu-IzneidT, et al.Neuroinflammatory markers: key indicators in the pathology of neurodegenerative diseases. Molecules2022; 27: 3194.
8.
EkundayoBEObafemiTOAdewaleOB, et al.Oxidative stress, endoplasmic reticulum stress and apoptosis in the pathology of Alzheimer’s disease. Cell Biochem Biophys2024; 82: 457–477.
9.
TziorasMMcGeachanRIDurrantCS, et al.Synaptic degeneration in Alzheimer disease. Nat Rev Neurol2023; 19: 19–38.
10.
RibaričS. Detecting early cognitive decline in Alzheimer’s disease with brain synaptic structural and functional evaluation. Biomedicines2023; 11: 355.
11.
ZhangHWeiWZhaoM, et al.Interaction between Aβ and tau in the pathogenesis of Alzheimer's disease. Int J Biol Sci2021; 17: 2181.
12.
RafiiMSAisenPS. Detection and treatment of Alzheimer’s disease in its preclinical stage. Nat Aging2023; 3: 520–531.
13.
KakkisED. The transformation of drug development for the 21st century: time for a change. Mol Genet Metab2022; 137: 107–113.
14.
GaoFWeiSDangL, et al.Sleep disturbance is associated with mild cognitive impairment: a community population-based cross-sectional study. BMC Public Health2022; 22: 2000.
15.
CasagrandeMForteGFavieriF, et al.Sleep quality and aging: a systematic review on healthy older people, mild cognitive impairment and Alzheimer’s disease. Int J Environ Res Public Health2022; 19: 8457.
16.
MayerGFrohnhofenHJokischM, et al.Associations of sleep disorders with all-cause MCI/dementia and different types of dementia–clinical evidence, potential pathomechanisms and treatment options: a narrative review. Front Neurosci2024; 18: 1372326.
17.
SlutskyI. Linking activity dyshomeostasis and sleep disturbances in Alzheimer disease. Nat Rev Neurosci2024; 25: 272–284.
18.
ShenYLvQ-kXieW-y, et al.Circadian disruption and sleep disorders in neurodegeneration. Transl Neurodegener2023; 12: 8.
19.
MukherjeeUSeharUBrownellM, et al.Mechanisms, consequences and role of interventions for sleep deprivation: focus on mild cognitive impairment and Alzheimer’s disease in elderly. Ageing Res Rev2024; 100: 102457.
20.
XuWTanC-CZouJ-J, et al.Insomnia moderates the relationship between amyloid-β and cognitive decline in late-life adults without dementia. J Alzheimers Dis2021; 81: 1701–1710.
21.
ShirolapovIZakharovASmirnovaD, et al.The role of the glymphatic clearance system in the mechanisms of the interactions of the sleep–waking cycle and the development of neurodegenerative processes. Neurosci Behav Physiol2024; 54: 199–204.
22.
van HattemTVerkaarLKrugliakovaE, et al.Targeting sleep physiology to modulate glymphatic brain clearance. Physiology (Bethesda)2025; 40: 271–290.
23.
WangXWangRLiJ. Influence of sleep disruption on protein accumulation in neurodegenerative diseases. Ageing Neur Dis2022; 2: 4.
24.
XiaoS-YLiuY-JLuW, et al.Possible neuropathology of sleep disturbance linking to Alzheimer’s disease: astrocytic and microglial roles. Front Cell Neurosci2022; 16: 875138.
25.
LewCHPetersenCNeylanTC, et al.Tau-driven degeneration of sleep-and wake-regulating neurons in Alzheimer’s disease. Sleep Med Rev2021; 60: 101541.
26.
MorroneCDRaghuramanRHussainiSA, et al.Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer’s disease. Mol Neurodegener2023; 18: 27.
27.
KeihaniAMayeliAFerrarelliF. Circadian rhythm changes in healthy aging and mild cognitive impairment. Adv Biol2023; 7: 2200237.
28.
SinghRBiswasDABiswasD. Physiological role of orexin/hypocretin in the human body in motivated behavior: a comprehensive review. Cureus2023; 15: e34009.
29.
ChatterjeeOGopalakrishnanLPullimamidiD, et al.A molecular network map of orexin-orexin receptor signaling system. J Cell Commun Signal2023; 17: 217–227.
30.
LiNHuangLZhangB, et al.The mechanism of different orexin/hypocretin neuronal projections in wakefulness and sleep. Brain Res2025; 1850: 149408.
31.
LiPZhuJZhangH, et al.The role of orexin and MCH neurons in the hypothalamus in sleep-wake regulation and learning-forgetting balance. Front Neurosci2025; 19: 1590556.
32.
ZhouMTangS. Effect of a dual orexin receptor antagonist on Alzheimer's disease: sleep disorders and cognition. Front Med2023; 9: 984227.
33.
Kourosh-AramiMRamezaniMKomakiA. The interaction between orexin, sleep deprivation and Alzheimer’s disease: unveiling an emerging connection. J Physiol Sci2025; 75: 100004.
34.
TreuSPPlanteDT. Cerebrospinal fluid orexin in Alzheimer's disease: a systematic review and meta-analysis. Sleep Med2021; 85: 230–238.
35.
LuRShahKToedebuschCD, et al.Associations of cerebrospinal fluid orexin-A, Alzheimer disease biomarkers, and cognitive performance. Ann Clin Transl Neurol2025; 12: 780–791.
36.
Kourosh-AramiMRamezaniMKomakiA. The interaction between orexin, sleep deprivation and Alzheimer’s disease: unveiling an emerging connection. J Physiol Sci2025; 75: 100004.
37.
ZhuangCCaoYLuJ, et al.The orexin/hypocretin system in dementia-related neurological disorders: a double-edged sword in cognitive impairment. Psychopharmacology (Berl)2025; 242: 2161–2179.
38.
UmYHLimHK. Orexin and Alzheimer’s disease: a new perspective. Psychiatry Investig2020; 17: 616.
39.
ZhuangCCaoYLuJ, et al.The orexin/hypocretin system in dementia-related neurological disorders: a double-edged sword in cognitive impairment. Psychopharmacology (Berl)2025; 242: 2161–2179.
40.
EbrahimIHowardRKopelmanM, et al.The hypocretin/orexin system. J R Soc Med2002; 95: 227–230.
41.
ZhangSWangPJiB, et al.Signal transduction, dimerization, and therapeutic targeting of Orexin and receptor systems. Front Pharmacol2025; 16: 1697406.
42.
KayabekirM. Neurophysiology of basic molecules affecting sleep and wakefulness mechanisms, fundamentals of sleep pharmacology. In: LarriveeD (ed.) Sleep Medicine and the Evolution of Contemporary Sleep Pharmacotherapy. IntechOpen, 2021. https://doi.org/10.5772/intechopen.100166.
43.
ChakrabortyDSChoudhurySLahiryS. Daridorexant, a recently approved dual orexin receptor antagonists (DORA) in treatment of insomnia. Sleep Sci2023; 16: 256–264.
44.
MuehlanCRochCVaillantC, et al.The orexin story and orexin receptor antagonists for the treatment of insomnia. J Sleep Res2023; 32: e13902.
45.
ŻełabowskiKPetrovWWojtysiakK, et al.Targeting the orexin system in the pharmacological management of insomnia and other diseases: suvorexant, lemborexant, daridorexant, and novel experimental agents. Int J Mol Sci2025; 26: 8700.
46.
MogaveroMPSilvaniALanzaG, et al.Targeting orexin receptors for the treatment of insomnia: from physiological mechanisms to current clinical evidence and recommendations. Nat Sci Sleep2023; 15: 17–38.
47.
YueJ-LChangX-WZhengJ-W, et al.Efficacy and tolerability of pharmacological treatments for insomnia in adults: a systematic review and network meta-analysis. Sleep Med Rev2023; 68: 101746.
48.
HanAHBurroughsCRFalgoustEP, et al.Suvorexant, a novel dual orexin receptor antagonist, for the management of insomnia. Health Psychol Res2023; 10: 67898.
49.
LechinFvan der DijsBAmatJ, et al.Neuroanatomical basis. In: LechinFvan der DijsB (eds) Neurochemistry and clinical disorders: circuitry of some psychiatric and psychosomatic syndromes. CRC Press, 1989, pp.1–48.
50.
Garcia-BorregueroDAragónAGMoncadaB, et al.Treatment of sleep, motor and sensory symptoms with the orexin antagonist suvorexant in adults with idiopathic restless legs syndrome: a randomized double-blind crossover proof-of-concept study. CNS Drugs2024; 38: 45–54.
51.
MisraS. A comprehensive review of dual orexin receptor antagonist (DORA), Daridorexant: novel drug for sleep and related disorders. Therapy2024; 1: 8.
52.
QueMLiYWangX, et al.Role of astrocytes in sleep deprivation: accomplices, resisters, or bystanders?Front Cell Neurosci2023; 17: 1188306.
53.
GanJXuZWenC, et al.Potential role of Amyloid-β on the association between Orexin-A and blood-brain barrier leakage of globus pallidus in Alzheimer’s disease and dementia with Lewy bodies. Alzheimers Res Ther2025; 17: 128.
54.
Morais dos SantosS. Exploring the intersection of artificial intelligence in understanding Alzheimer’s Disease: the role of the circadian clock and orexin receptors. Master's Thesis, Universidade de Lisboa, Portugal, 2024.
55.
LiESongFCoppolaQ, et al.Treatment of disturbed sleep in progressive supranuclear palsy: a randomized, remote, double-blinded, 6-week cross-over design study protocol comparing zolpidem, suvorexant, and placebo. Trials2026; 27: 105.
56.
CarpiMMercuriNBLiguoriC. Orexin receptor antagonists for the prevention and treatment of Alzheimer’s disease and associated sleep disorders. Drugs2024; 84: 1365–1378.
57.
RagsdaleSRadovichJCoidurasI, et al.Dual orexin receptor antagonists as promising therapeutics for Alzheimer’s disease. NPJ Biol Timing Sleep2025; 2: 11.
58.
KronJO-ZKeenanRJHoyerD, et al.Orexin receptor antagonism: normalizing sleep architecture in old age and disease. Annu Rev Pharmacol Toxicol2024; 64: 359–386.
59.
LuceyBPLiuHToedebuschCD, et al.Suvorexant acutely decreases tau phosphorylation and aβ in the human CNS. Ann Neurol2023; 94: 27–40.
60.
LuceyBP. Sleep alterations and cognitive decline. Semin Neurol2025; 45: 333–347.
61.
OliveiraPA. The impact of sleep-wake interventions on neuropathology and cognition in a mouse model of dementia. PhD Thesis, University of Surrey, UK, 2021.
62.
GuoXYueRCuiZ, et al.Advances of therapeutic strategies for Alzheimer’s disease. J Neurol2025; 272: 705.
63.
ZhouFYanX-DWangC, et al.Suvorexant ameliorates cognitive impairments and pathology in APP/PS1 transgenic mice. Neurobiol Aging2020; 91: 66–75.
64.
KeenanRJDaykinHMethaJ, et al.Orexin 2 receptor antagonism sex-dependently improves sleep/wakefulness and cognitive performance in tau transgenic mice. Br J Pharmacol2024; 181: 87–106.
65.
ParmarSTadavartyRSastryBR. G-protein coupled receptors and synaptic plasticity in sleep deprivation. World J Psychiatry2021; 11: 954.
66.
UğuzACDoğanyiğitZ, et al.Structural and synaptic plasticity in the hippocampus. In: TurgutMAcerNTurgutAT (eds) The human hippocampus: development, neuroanatomy, neurophysiology, neuropathology and surgery. Springer, 2025, pp.49–75.
67.
LiuK. Circadian rhythm disruption and sleep disorders in Alzheimer’s disease: mechanistic insights and therapeutic potentials. Neuroendocrinol Lett2025; 46: 59–69.
68.
Alexandra LopesPGuil-GuerreroJL. Beyond Transgenic mice: emerging models and translational strategies in Alzheimer’s disease. Int J Mol Sci2025; 26: 5541.
69.
ToorBRayLBPozzobonA, et al.Sleep, orexin and cognition. Front Neurol Neurosci2021; 45: 38–51.
70.
ZhuangCYanHLuJ, et al.Compensatory enhancement of orexinergic system functionality induced by amyloid-β protein: a neuroprotective response in Alzheimer’s disease. Front Physiol2025; 16: 1529981.
71.
LefterRCojocariuROCiobicaA, et al.Interactions between sleep and emotions in humans and animal models. Medicina (B Aires)2022; 58: 274.
72.
YuYShaoNZhangX, et al.Mitigation of learning and memory impairment caused by acute total sleep deprivation through OX1R/OX2R-mediated hippocampal neurogenesis in rats. Exp Gerontol2025; 206: 112769.
73.
ThangwaritornSLeeCMetchikoffE, et al.A review of recent advances in the management of Alzheimer’s disease. Cureus2024; 16: e58416.
74.
BlackmanJSwirskiMClynesJ, et al.Pharmacological and non-pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: a systematic review. J Sleep Res2021; 30: e13229.
75.
HerringWJCeesayPSnyderE, et al.Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. Alzheimers Dement2020; 16: 541–551.
76.
AldurdunjiMM. Management of sleep disturbance related to Alzheimer disease and dementia: an updated review of ClinicalTrials. gov. Medicine2025; 104: e43725.
77.
CafaroRMacellaroMSuppesT, et al.A double-blind, randomized, placebo-controlled plus open trial of adjunctive suvorexant for treatment-resistant insomnia in patients with bipolar disorder. CNS Spectr2024; 29: 376–384.
78.
ZeitzerJMJoyceDSMcBeanA, et al.Effect of suvorexant vs placebo on total daytime sleep hours in shift workers: a randomized clinical trial. JAMA Netw Open2020; 3: e206614–e206614.
79.
RolandJPBliwiseDL. Impact of pharmacotherapy on insomnia in patients with Alzheimer’s disease. Drugs Aging2021; 38: 951–966.
80.
de OliveiraHMRuelasMGZamoraFV, et al.Efficacy of ramelteon, suvorexant, and lemborexant for delirium prevention in hospitalized patients: a systematic review and meta-analysis. Crit Care Med2025; 53: e1781–e1789.
81.
CordoneSScarpelliSAlfonsiV, et al.Sleep-based interventions in Alzheimer’s disease: promising approaches from prevention to treatment along the disease trajectory. Pharmaceuticals2021; 14: 383.
82.
CarpiMFernandesMMercuriNB, et al.Sleep biomarkers for predicting cognitive decline and Alzheimer’s disease: a systematic review of longitudinal studies. J Alzheimers Dis2024; 97: 121–143.
AlshibanAHasogluTOsterJ. Efficacy and safety of dual orexin receptor antagonist (DORA) for sleep disturbance in patients with Alzheimer's disease dementia. A review article. Am J Geriatr Psychiatry2025; 33: 209–218.
85.
KimW-JKimH-S. Emerging and upcoming therapies in insomnia. Transl Clin Pharmacol2024; 32: 1.
86.
SingerCTractenbergREKayeJ, et al.A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep2003; 26: 893–901.
87.
BergerAASottosantiERWinnickA, et al.Suvorexant in the treatment of difficulty falling and staying asleep (Insomnia). Psychopharmacol Bull2022; 52: 68.
BouâoudaHJhaPK. Orexin and MCH neurons: regulators of sleep and metabolism. Front Neurosci2023; 17: 1230428.
90.
PierreNBaiwirDHuynh-ThuVA, et al.Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn’s patients: a proteomics-based study. Gut2021; 70: 1450–1457.
91.
StephenRBarberaMPetersR, et al.Development of the first WHO guidelines for risk reduction of cognitive decline and dementia: lessons learned and future directions. Front Neurol2021; 12: 763573.
92.
Lopes AlvesIHeemanFCollijLE, et al.Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging. Alzheimers Res Ther2021; 13: 82.
93.
Di MarcoTDjonlagicIDauvilliersY, et al.Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder: a pooled post hoc analysis of two randomized phase 3 clinical studies. Sleep2024; 47: zsae098.
94.
ReidMJDunnKEAbrahamL, et al.Suvorexant alters dynamics of the sleep-electroencephalography-power spectrum and depressive-symptom trajectories during inpatient opioid withdrawal. Sleep2024; 47: zsae025.
95.
LüWDuanJZhangW, et al.Relationship between neuropsychiatric symptoms and cognitive functions in patients with cognitive impairment. Psychogeriatrics2021; 21: 773–782.
96.
VerduzcoADRSalariAHaghparastP. Efficacy and safety of pharmacotherapy in chronic insomnia: a review of clinical guidelines and case reports. Ment Health Clin2023; 13: 244–254.
97.
SabatAGargAKhanMA. Efficacy and safety profile of suvorexant for the treatment of insomnia. Curr Drug Saf2025; 21: 56–68.
PlessAWareDSagguS, et al.Understanding neuropsychiatric symptoms in Alzheimer’s disease: challenges and advances in diagnosis and treatment. Front Neurosci2023; 17: 1263771.
100.
HoelRWConnollyRMGTakahashiPY. Polypharmacy management in older patients. Mayo Clin Proc2021; 96: 242–256.
101.
KunzDDauvilliersYBenesH, et al.Long-term safety and tolerability of daridorexant in patients with insomnia disorder. CNS Drugs2023; 37: 93–106.
102.
ShirolapovIZakharovASmirnovaD, et al.The role of glymphatic clearance in the mechanisms linking the sleep–wake cycle with the development of neurodegenerative processes. Neurosci Behav Physiol2024; 54: 398–403.
103.
YangHTianXLuoX, et al.Glymphatic system dysfunction: a link between sleep disorders and neurodegeneration. Psychopharmacology (Berl). Epub ahead of print 24 Jan 2026. DOI: https://doi.org/10.1007/s00213-026-07004-z
104.
AssisDSL. In silico discovery and optimization of small molecules targeting neurodegenerative diseases. Master's Degree, Universidade de Lisboa, Portugal, 2024.
105.
van HattemTVerkaarLKrugliakovaE, et al.Targeting sleep physiology to modulate glymphatic brain clearance. Physiology2025; 40: 271–290.
106.
PivacLN. Sleep Improvement: A Preventative Therapy to Reduce the Risk for Cognitive Decline. PhD Thesis, Murdoch University, Australia, 2025.
107.
JagirdarRFuC-HParkJ, et al.Restoring activity in the thalamic reticular nucleus improves sleep architecture and reduces Aβ accumulation in mice. Sci Transl Med2021; 13: eabh4284.
108.
Garcia-EscobarGManeroRMFernández-LebreroA, et al.Blood biomarkers of Alzheimer’s disease and cognition: a literature review. Biomolecules2024; 14: 93.
109.
FišarZ. Linking the amyloid, tau, and mitochondrial hypotheses of Alzheimer’s disease and identifying promising drug targets. Biomolecules2022; 12: 1676.
110.
OyovwiMOBabawaleKHJerohE, et al.Exploring the role of neuromodulation in neurodegenerative disorders: insights from Alzheimer's and Parkinson's diseases. Brain Disord2025; 17: 100187.
111.
ZhangWLianTHeM, et al.Sleep disorders and Alzheimer’s disease: relationship and mechanisms involving neuroinflammation, orexin and Aβ. Fluids Barriers CNS2025; 22: 62.
112.
AbikenariMHaJHLiuJ, et al.The immunological landscape of traumatic brain injury: insights from pathophysiology to experimental models. Front Neurol2025; 16: 1668480.
113.
InoueYKoebisM. Comprehensive understanding of the treatment of insomnia with lemborexant. Expert Rev Clin Pharmacol2025; 18: 785–796.
114.
KylkilahtiTMBerendsERamosM, et al.Achieving brain clearance and preventing neurodegenerative diseases—A glymphatic perspective. J Cereb Blood Flow Metab2021; 41: 2137–2149.
115.
DranitsarisGZhangQMuL, et al.Therapeutic preference for Alzheimer’s disease treatments: a discrete choice experiment with caregivers and neurologists. Alzheimers Res Ther2023; 15: 60.
116.
PerreyDAZhangY. Therapeutics development for addiction: orexin-1 receptor antagonists. Brain Res2020; 1731: 145922.
Camberos-BarrazaJCamacho-ZamoraABátiz-BeltránJC, et al.Sleep, glial function, and the endocannabinoid system: implications for neuroinflammation and sleep disorders. Int J Mol Sci2024; 25: 3160.
119.
ColomboG. Orexinergic and cholinergic function in the brain ascending modulatory system and its implications in sleep-related pathologies. PhD Thesis, Università degli Studi di Milano-Bicocca, Italy, 2022.
120.
RuanWYuanXEltzschigHK. Circadian rhythm as a therapeutic target. Nat Rev Drug Discov2021; 20: 287–307.
121.
CarpiMMercuriNBLiguoriC. Orexin receptor antagonists for the prevention and treatment of Alzheimer’s disease and associated sleep disorders. Drugs2024; 84: 1365.
122.
VoumvourakisKISideriEPapadimitropoulosGN, et al.The dynamic relationship between the glymphatic system, aging, memory, and sleep. Biomedicines2023; 11: 2092.
123.
LengFEdisonP. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?Nat Rev Neurol2021; 17: 157–172.
124.
Otero-LópezPMadrid-GonzálezXFernández-DueñasV, et al.Awakening recovery: enhancing orexinergic tone after acute CNS damage. Pharmaceuticals2025; 18: 1879.
125.
GurusamyKSMoherDLoizidouM, et al.Clinical relevance assessment of animal preclinical research (RAA) tool: development and explanation. PeerJ2021; 9: e10673.
126.
FernandezF-XGrandnerMA. Amyloid-β as a cytokine-like somnogen: rethinking its role in sleep homeostasis and Alzheimer's disease. J Alzheimers Dis2026; 109: 70–83.
127.
SiripaopraditYChatsirisakulOAriyapaisalkulT, et al.Exploring the gut-brain axis in Alzheimer’s disease treatment via probiotics: evidence from animal studies-a systematic review and meta-analysis. BMC Neurol2024; 24: 481.
128.
MoaddelRUbaida-MohienCTanakaT, et al.Proteomics in aging research: a roadmap to clinical, translational research. Aging Cell2021; 20: e13325.
129.
KangJHKoreckaMLeeEB, et al.Alzheimer disease biomarkers: moving from CSF to plasma for reliable detection of amyloid and tau pathology. Clin Chem2023; 69: 1247–1259.
130.
PascoalTAAguzzoliCSLussierFZ, et al.Insights into the use of biomarkers in clinical trials in Alzheimer's disease. EBioMedicine2024; 108: 105322.
131.
RaufRAsifSAlSaafeenA, et al.Orexin deficiency in narcolepsy: molecular mechanisms, clinical phenotypes, and emerging therapeutic frontiers. Brain Behav2025; 15: e70984.
132.
15th Conference Clinical Trials Alzheimer’s Disease, November 29-December 2, 2022, San Francisco, CA, USA: Symposia - Oral Communications - Late Breaking Abstracts (Clinical Trial Alzheimer’s Disease). J Prev Alzheimers Dis2022; 9: 8–50.
133.
YehWCLiYSChangYP, et al.The efficacy and safety of dual orexin receptor antagonists in obstructive sleep apnea: a systematic review and meta-analysis of randomised controlled trials. J Sleep Res2025; 34: e14399.
134.
GarbarinoSBragazziNL. Revolutionizing sleep health: the emergence and impact of personalized sleep medicine. J Pers Med2024; 14: 598.
135.
ComaiSManchiaMBosiaM, et al.Moving toward precision and personalized treatment strategies in psychiatry. Int J Neuropsychopharmacol2025; 28: pyaf025.
136.
XiaoXRuiYJinY, et al.Relationship of sleep disorder with neurodegenerative and psychiatric diseases: an updated review. Neurochem Res2024; 49: 568–582.
137.
WuS-HChengW-JChenL-J, et al.Moderate-intensity continuous exercise preserves sleep quality, while high-intensity intermittent exercise disrupts it in female night-shift healthcare workers. Sci Rep2025; 15: 24428.
138.
BuongiornoMGranellECaruanaG, et al.Impairments in sleep and brain molecular clearance in people with cognitive deterioration and biological evidence of AD: a report of four cases. BMC Neurol2023; 23: 417.
139.
FonsecaCSBakerSLDobynsL, et al.Tau accumulation and atrophy predict amyloid independent cognitive decline in aging. Alzheimers Dement2024; 20: 2526–2537.
140.
Cuestas TorresDMCardenasFP. Synaptic plasticity in Alzheimer’s disease and healthy aging. Rev Neurosci2020; 31: 245–268.
WitcherKGBrayCEChunchaiT, et al.Traumatic brain injury causes chronic cortical inflammation and neuronal dysfunction mediated by microglia. J Neurosci2021; 41: 1597–1616.
143.
NigroEArgentinoFMusumeciG, et al.Orexin and lifestyle habits: a meaningful connection among nutrition, physical activity, and sleep pattern in health and diseases. Int J Mol Sci2025; 26: 8980.
144.
BergamoGLiguoriC. Are sleep disturbances modifiable risk factors for mild cognitive impairment and dementia? A systematic review of large studies. Sleep Breath2025; 29: 269.
145.
LuceyBPWischJBoerwinkleAH, et al.Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimer’s disease. Brain2021; 144: 2852–2862.
146.
ChandrasekharaSYuS-JS. Chapter 8. Sedative, hypnotic, and anxiolytic use and use disorder among older adults. In: WalaszekA (eds) Substance use in older adults. American Psychiatric Publishing, 2024, pp.213–240.
147.
McClintockKTMercurioAKReillyDS, et al.Sleep: architecture, deprivation, and propofol-induced sleep. AANA J2024; 92: 459–470.
148.
DiasDSocodatoR. Beyond amyloid and tau: the critical role of microglia in Alzheimer’s disease therapeutics. Biomedicines2025; 13: 279.
149.
ZetterbergHBendlinBB. Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies. Mol Psychiatry2021; 26: 296–308.
150.
YuYWangJXuJ. Optimal dose and type of exercise to improve cognitive function in patients with mild cognitive impairment: a systematic review and network meta-analysis of RCTs. Front Psychiatry2024; 15: 1436499.
151.
HuynhQ-SElangovanSHolsingerRD. Non-pharmacological therapeutic options for the treatment of Alzheimer’s disease. Int J Mol Sci2022; 23: 11037.
152.
Fourie ZirkelbachJShahMVallejoJ, et al.Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients. J Clin Oncol2022; 40: 3489–3500.
153.
HameedAKAsiriMFedwiMM, et al.The efficacy and safety of trazodone for sleep problems in depressive patients: a GRADE-assessed systematic review and meta-analysis of clinical trials. Psychopharmacology (Berl)2026; 243: 457–473.
154.
Falup-PecurariuCMunteanM-LUngureanuL, et al.Pharmacological and non-pharmacological management of sleep disturbances in Parkinson’s disease: if when and how. Expert Opin Pharmacother2024; 25: 2135–2149.
155.
JavedBJavedAKowCS, et al.Pharmacological and non-pharmacological treatment options for sleep disturbances in Alzheimer’s disease. Expert Rev Neurother2023; 23: 501–514.
156.
KhoshnevisSSmolenskyMHHaghayeghS, et al.Recommended timing of medications that impact sleep and wakefulness: a review of the American Prescribers’ digital reference. Sleep Med Rev2023; 67: 101714.
157.
BlandHLiXManginE, et al.Effects of bedtime dosing with suvorexant and zolpidem on balance and psychomotor performance in healthy elderly participants during the night and in the morning. J Clin Psychopharmacol2021; 41: 414–420.
158.
PalaginiLBianchiniC. Pharmacotherapeutic management of insomnia and effects on sleep processes, neural plasticity, and brain systems modulating stress: a narrative review. Front Neurosci2022; 16: 893015.
159.
ZeitzerJMJoyceDSMcBeanA, et al.Effect of suvorexant vs placebo on total daytime sleep hours in shift workers: a randomized clinical trial. JAMA Netw Open2020; 3: e206614.
160.
MuehlanCVaillantCZenklusenI, et al.Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opin Drug Metab Toxicol2020; 16: 1063–1078.
161.
MittalNMittalRGuptaM. Zolpidem for insomnia: a double-edged sword. A systematic literature review on Zolpidem-induced complex sleep behaviors. Indian J Psychol Med2021; 43: 373–381.
162.
NiJJinLZhaoD, et al.Pharmacokinetics, pharmacodynamic, safety and tolerability of fazamorexant, a novel dual orexin receptor antagonist: report of the first-in-human study. Drug Des Devel Ther2025; 19: 5271–5282.
163.
SobolewskiK. Sedatives and hypnotics. In: RaySD (eds) Side effects of drugs annual. Elsevier, 2021, pp.79–87.
